We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Hormone Treatment for Female Infertility

By HospiMedica staff writers
Posted on 04 Sep 2000
Clinical studies show that a recombinant human luteinizing hormone (LH) is a safe, effective treatment for women with an endocrine form of infertility. More...
Given in addition to Gonal-F (recombinant human FSH), the drug promoted hormone production by the ovaries, so that follicular development and preparation of the uterine lining took place in a majority of patients.

The drug, called Luveris (lutropin alfa), will allow doctors to individualize dosing of LH and FSH, offering greater treatment flexibility. Developed by Serono S.A. (Geneva, Switzerland), Luveris is suitable for subcutaneous injection by the patient. Serono says it will obviate the need for doctors to use urine-derived human menopausal gonadotropins, which contain only a limited amount of gonadotropins. According to the company, Luveris is the first pure luteinizing hormone available for the treatment of female infertility. The drug has been recommended for marketing by the European Medicines Evaluation Agency (EMEA).

In 1995, Serono introduced Gonal-F, the first product derived from recombinant DNA technology for the treatment of infertility. With Luveris, the company will become the first to offer a totally recombinant gonadotropin portfolio.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Resorbable Bovine Collagen Membrane
GenDerm
Tourniquet System
heidi– mein Tourniquet
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.